Yeku O - Search Results

1

Targeting galectin-3 with a high-affinity antibody for inhibition of high-grade serous ovarian cancer and other MUC16/CA-125-expressing malignancies.

Stasenko M, Smith E, Yeku O, Park KJ, Laster I, Lee K, Walderich S, Spriggs E, Rueda B, Weigelt B, Zamarin D, Rao TD, Spriggs DR. Stasenko M, et al. Among authors: yeku o. Sci Rep. 2021 Feb 12;11(1):3718. doi: 10.1038/s41598-021-82686-3. Sci Rep. 2021. PMID: 33580170 Free PMC article.

2

Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment.

Yeku OO, Purdon TJ, Koneru M, Spriggs D, Brentjens RJ. Yeku OO, et al. Sci Rep. 2017 Sep 5;7(1):10541. doi: 10.1038/s41598-017-10940-8. Sci Rep. 2017. PMID: 28874817 Free PMC article.

3

Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and through Activation of the Endogenous Immune System.

Avanzi MP, Yeku O, Li X, Wijewarnasuriya DP, van Leeuwen DG, Cheung K, Park H, Purdon TJ, Daniyan AF, Spitzer MH, Brentjens RJ. Avanzi MP, et al. Among authors: yeku o. Cell Rep. 2018 May 15;23(7):2130-2141. doi: 10.1016/j.celrep.2018.04.051. Cell Rep. 2018. PMID: 29768210 Free PMC article.

4

Losartan treatment enhances chemotherapy efficacy and reduces ascites in ovarian cancer models by normalizing the tumor stroma.

Zhao Y, Cao J, Melamed A, Worley M, Gockley A, Jones D, Nia HT, Zhang Y, Stylianopoulos T, Kumar AS, Mpekris F, Datta M, Sun Y, Wu L, Gao X, Yeku O, Del Carmen MG, Spriggs DR, Jain RK, Xu L. Zhao Y, et al. Among authors: yeku o. Proc Natl Acad Sci U S A. 2019 Feb 5;116(6):2210-2219. doi: 10.1073/pnas.1818357116. Epub 2019 Jan 18. Proc Natl Acad Sci U S A. 2019. PMID: 30659155 Free PMC article.

5

A phase 2 study of combined chemo-immunotherapy with cisplatin-pembrolizumab and radiation for unresectable vulvar squamous cell carcinoma.

Yeku O, Russo AL, Lee H, Spriggs D. Yeku O, et al. J Transl Med. 2020 Sep 14;18(1):350. doi: 10.1186/s12967-020-02523-5. J Transl Med. 2020. PMID: 32928237 Free PMC article. Clinical Trial.

6

Bispecific T-Cell Engaging Antibodies Against MUC16 Demonstrate Efficacy Against Ovarian Cancer in Monotherapy and in Combination With PD-1 and VEGF Inhibition.

Yeku OO, Rao TD, Laster I, Kononenko A, Purdon TJ, Wang P, Cui Z, Liu H, Brentjens RJ, Spriggs D. Yeku OO, et al. Front Immunol. 2021 Apr 14;12:663379. doi: 10.3389/fimmu.2021.663379. eCollection 2021. Front Immunol. 2021. PMID: 33936101 Free PMC article.

7

Effect of Mismatch Repair Status on Outcome of Early-Stage Grade 1 to 2 Endometrial Cancer Treated With Vaginal Brachytherapy.

Russo AL, Lee LJ, Wo JY, Niemierko A, Park D, Alban G, King M, Philp L, Growdon WB, Oliva E, Spriggs DR, Yeku OO. Russo AL, et al. Among authors: yeku oo. Am J Clin Oncol. 2022 Jan 1;45(1):36-39. doi: 10.1097/COC.0000000000000871. Am J Clin Oncol. 2022. PMID: 34817442

8

Dual Fluorescence Isogenic Synthetic Lethal Kinase Screen and High-Content Secondary Screening for MUC16/CA125-Selective Agents.

Rao TD, Xu M, Eng S, Yang G, Manson R, Rosales N, Kumar R, Veillard IE, Zhou Q, Iasonos A, Ouerfelli O, Djaballah H, Spriggs DR, Yeku OO. Rao TD, et al. Among authors: yeku oo. Mol Cancer Ther. 2022 May 4;21(5):775-785. doi: 10.1158/1535-7163.MCT-21-0572. Mol Cancer Ther. 2022. PMID: 35413118 Free PMC article.

9

Evaluation of Treatment With Talazoparib and Avelumab in Patients With Recurrent Mismatch Repair Proficient Endometrial Cancer.

Konstantinopoulos PA, Gockley AA, Xiong N, Krasner C, Horowitz N, Campos S, Wright AA, Liu JF, Shea M, Yeku O, Castro C, Polak M, Lee EK, Sawyer H, Bowes B, Moroney J, Cheng SC, Tayob N, Bouberhan S, Spriggs D, Penson RT, Fleming GF, Nucci MR, Matulonis UA. Konstantinopoulos PA, et al. Among authors: yeku o. JAMA Oncol. 2022 Sep 1;8(9):1317-1322. doi: 10.1001/jamaoncol.2022.2181. JAMA Oncol. 2022. PMID: 35900726 Free PMC article. Clinical Trial.

10

Phase IIa Study of PLX2853 in Gynecologic Cancers With Known ARID1A Mutation and Phase Ib/IIa Study of PLX2853/Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer.

Duska LR, Zamarin D, Hamilton E, Oza A, Fleming G, Spira A, Yeku OO, Richardson DL, Walling J, Inokuchi K, Matusow B, Bollag G, Swisher EM. Duska LR, et al. Among authors: yeku oo. JCO Precis Oncol. 2023 Sep;7:e2300235. doi: 10.1200/PO.23.00235. JCO Precis Oncol. 2023. PMID: 37797273 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

41 results

Search Page